A detailed history of Russell Investments Group, Ltd. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 47,649 shares of CTMX stock, worth $51,937. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,649
Previous 42,814 11.29%
Holding current value
$51,937
Previous $52,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.12 - $1.51 $5,415 - $7,300
4,835 Added 11.29%
47,649 $56,000
Q2 2024

Aug 08, 2024

BUY
$1.21 - $5.13 $19 - $82
16 Added 0.04%
42,814 $52,000
Q1 2024

May 08, 2024

BUY
$1.41 - $2.74 $1,512 - $2,940
1,073 Added 2.57%
42,798 $93,000
Q4 2023

Feb 05, 2024

SELL
$1.07 - $1.55 $4,174 - $6,046
-3,901 Reduced 8.55%
41,725 $64,000
Q3 2023

Nov 13, 2023

SELL
$1.26 - $1.87 $10,179 - $15,107
-8,079 Reduced 15.04%
45,626 $58,000
Q2 2023

Aug 10, 2023

SELL
$1.41 - $1.92 $4,723 - $6,432
-3,350 Reduced 5.87%
53,705 $92,000
Q1 2023

May 09, 2023

SELL
$1.48 - $2.88 $1,764 - $3,432
-1,192 Reduced 2.05%
57,055 $86,000
Q4 2022

Feb 08, 2023

SELL
$1.19 - $1.91 $3,656 - $5,869
-3,073 Reduced 5.01%
58,247 $93,000
Q3 2022

Nov 04, 2022

SELL
$1.23 - $1.97 $214,204 - $343,075
-174,150 Reduced 73.96%
61,320 $88,000
Q2 2022

Jul 29, 2022

BUY
$1.53 - $2.89 $229,639 - $433,762
150,091 Added 175.79%
235,470 $429,000
Q1 2022

May 05, 2022

SELL
$2.67 - $4.68 $121,944 - $213,744
-45,672 Reduced 34.85%
85,379 $227,000
Q4 2021

Jan 21, 2022

SELL
$3.87 - $7.39 $136,839 - $261,303
-35,359 Reduced 21.25%
131,051 $567,000
Q3 2021

Nov 08, 2021

SELL
$4.32 - $6.43 $8,868 - $13,200
-2,053 Reduced 1.22%
166,410 $846,000
Q2 2021

Aug 04, 2021

SELL
$6.33 - $9.91 $101,564 - $159,005
-16,045 Reduced 8.7%
168,463 $1.07 Million
Q1 2021

May 10, 2021

SELL
$6.6 - $9.0 $288,644 - $393,606
-43,734 Reduced 19.16%
184,508 $1.42 Million
Q4 2020

Feb 08, 2021

SELL
$6.47 - $7.9 $1.68 Million - $2.05 Million
-259,428 Reduced 53.2%
228,242 $1.5 Million
Q3 2020

Nov 09, 2020

BUY
$6.55 - $8.83 $2.52 Million - $3.4 Million
384,490 Added 372.64%
487,670 $3.24 Million
Q2 2020

Aug 05, 2020

BUY
$7.4 - $14.64 $68,094 - $134,717
9,202 Added 9.79%
103,180 $857,000
Q1 2020

May 06, 2020

BUY
$3.61 - $8.6 $180,803 - $430,722
50,084 Added 114.1%
93,978 $718,000
Q4 2019

Jan 29, 2020

BUY
$5.17 - $8.91 $226,931 - $391,095
43,894 New
43,894 $363,000
Q4 2018

Feb 11, 2019

SELL
$12.69 - $18.61 $320,397 - $469,865
-25,248 Closed
0 $0
Q3 2018

Oct 26, 2018

SELL
$18.04 - $26.41 $1.83 Million - $2.68 Million
-101,571 Reduced 80.09%
25,248 $467,000
Q2 2018

Aug 08, 2018

SELL
$21.38 - $29.68 $1.38 Million - $1.91 Million
-64,382 Reduced 33.67%
126,819 $2.9 Million
Q1 2018

May 11, 2018

BUY
$21.76 - $34.22 $1.82 Million - $2.86 Million
83,448 Added 77.44%
191,201 $5.44 Million
Q4 2017

Feb 06, 2018

BUY
$19.0 - $23.09 $1.75 Million - $2.13 Million
92,305 Added 597.52%
107,753 $2.38 Million
Q3 2017

Nov 07, 2017

BUY
$13.53 - $18.17 $209,011 - $280,690
15,448
15,448 $281,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $71.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.